Publication date: Nov 15, 2024
For example, combining bedaquiline with another antibiotic called isoniazid appeared to prevent the development of resistance to either drug, he said. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development strategies. It also could also guide the development of new drugs or drug combinations. “We’re developing machine-learning tools to understand other changes that are occurring in TB biology or TB physiology caused by other kinds of drug resistance,” Yang said. Approved in 2012 by the U. S. Food and Drug Administration (FDA), bedaquiline was the first new TB drug in more than 40 years. “We can prevent resistance by developing other drugs that make bedaquiline work better,” Yang said. This catalase deficiency leads to several changes that make the bacteria more vulnerable to the newer drug.
| Concepts | Keywords |
|---|---|
| Annually | Antibiotic |
| Deadliest | Bacteria |
| Drugs | Bedaquiline |
| Mycobacterium | Drug |
| Tailoring | Drugs |
| Findings | |
| Prevent | |
| Resistance | |
| Resistant | |
| Said | |
| Strains | |
| Tb | |
| Tuberculosis | |
| Works | |
| Yang |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | antibiotic resistance |
| drug | DRUGBANK | Isoniazid |
| disease | MESH | infectious diseases |
| drug | DRUGBANK | Tropicamide |
| drug | DRUGBANK | Bedaquiline |
| disease | IDO | bacteria |
| pathway | KEGG | Tuberculosis |
| disease | MESH | tuberculosis |
| disease | MESH | infections |
| disease | MESH | causes |
| disease | MESH | catalase deficiency |
| disease | IDO | susceptibility |
| disease | MESH | DNA damage |
| drug | DRUGBANK | Trimethoprim |
| drug | DRUGBANK | Sulfamethoxazole |
| disease | IDO | process |